T

his year’s biotech IPO waters are showing their first hints of turbulence.

Braeburn Pharmaceuticals, which last year got approval for an implant that dispenses medicine to treat opioid addiction, had planned to go public this week to raise up to $150 million. But on Thursday the company said in an emailed statement that it was scrapping its IPO plans for now, having “concluded that the current market environment does not represent an appropriate financing opportunity.”

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.

Recommended Stories